The short answer to this question is that it already did. Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company developing next-generation biologics for inflammatory and immunological diseases, was acquired by AbbVie Inc. (ABBV) for $135.11 per share in cash. Apogee's common stock ceased trading on Nasdaq on September 3, 2026, and shareholders received the deal consideration in full. What follows is a record of how that $135 level was reached and what it represented.
Before the acquisition, Wall Street targets for Apogee spanned a wide range. Around April 2026, published forecasts ranged from roughly $82 to $168, with an average near $119, according to aggregated data from Fintel and Nasdaq. That dispersion reflected genuine disagreement about the commercial potential of zumilokibart and the rest of Apogee's pipeline.
The picture changed abruptly on June 18, 2026, when AbbVie and Apogee announced a definitive merger agreement. Because the deal fixed the terminal value of each share at $135.11 in cash, analysts had little reason to publish targets meaningfully above or below that figure. In the weeks that followed, firms including Mizuho, RBC Capital, Deutsche Bank, Truist Securities, and Wedbush revised their price targets toward $135, and the average analyst price target effectively collapsed onto the deal price. This convergence was an arithmetic consequence of an all-cash takeover, not a change in fundamentals.
Apogee's last reported trading range over the trailing year was approximately $35.39 to $135.09, according to Nasdaq data. The stock's final days of trading hovered just below the $135.11 deal price as the market arbitraged the small remaining gap to completion. Because the acquisition is complete, there is no remaining "upside" to calculate: the path toward $135 was a merger-arbitrage path, resolved when the transaction closed and Apogee shareholders were paid in cash.
It is worth noting how the target was reached. The $135.11 price represented a premium of roughly 47% to 49% over Apogee's closing price immediately before the announcement — a meaningful premium reflecting the strategic value AbbVie assigned to Apogee's immunology pipeline rather than a gradual re-rating driven by quarterly results.
The factors that supported the move toward $135 were primarily strategic and clinical. Apogee's lead program, zumilokibart (APG777), is an anti-IL-13 antibody with potential differentiated efficacy and dosing for atopic dermatitis and other inflammatory indications, alongside additional pipeline assets such as APG273. AbbVie, a leader in immunology, viewed the asset as a natural extension of its franchise. The definitive agreement, unanimously approved by both boards and subsequently by Apogee shareholders at a special meeting on August 11, 2026, removed execution risk for Apogee investors, who received a fixed cash price regardless of future clinical outcomes.
Before the deal was signed and approved, several risks could have prevented Apogee from reaching $135 on its own. As a clinical-stage company with no product revenue, Apogee was unprofitable; consensus earnings estimates remained negative into the late 2020s. The value of the enterprise rested on the success of clinical trials that had not yet delivered registrational data, and early-stage readouts are not reliably predictive of later results. Regulatory, competitive, and financing risks were also material. Once the merger agreement was in place, the principal remaining risk was deal-related: failure to obtain shareholder or regulatory approval, or a termination of the agreement, could have sent the stock back toward its pre-deal levels. None of these risks materialized, and the transaction closed as planned.
There is no longer a research horizon for Apogee as a standalone security, because the company no longer trades. Investors with an interest in the underlying science now monitor it through AbbVie, which has stated that the acquisition is expected to reduce its adjusted diluted earnings per share by about $0.14 in 2026 and roughly $0.46 in 2027, before becoming accretive beginning around 2032. Relevant items to watch going forward include clinical data readouts for zumilokibart and the integration of Apogee's pipeline into AbbVie's immunology portfolio.
For traders navigating active, liquid securities, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to keep pace with changing markets. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use it to discover new opportunities, monitor existing positions, and spot emerging trends more efficiently than manual screening alone. Explore the AI Daily Buy/Sell Signals to see how automated signal generation can support your research process.
The central target of $135 for Apogee Therapeutics is not a speculative forecast but the all-cash price at which the company was acquired and delisted. After a wide pre-deal range of analyst targets, Wall Street's figures converged on the $135.11 deal value, which AbbVie ultimately paid in full. The move toward that level was driven by strategic interest in Apogee's lead asset, zumilokibart, and the target was reached through completion of the merger rather than through operational performance. For Apogee as an independent ticker, the question of reaching $135 is settled; for investors following the underlying science, the story now continues within AbbVie.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.